Health Technology Dr. Reddy's Laboratories Ltd. Business Summary
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Financial Highlights
Mar 2021
INR USD Revenue 189,722M 2,555.69M Gross Profit 96,342M 1,297.79M Operating income 32,028M 431.44M Income before tax 25,933M 349.33M Net income 17,238M 232.20M EBITDA 44,824M 603.81M Diluted EPS 103.64 1.39 Dividends Per Share 25 0.33 Total Assets 265,491M 3,631.20M Total liabilities 92,429M 1,264.18M Total equity 173,062M 2,367.02M Operating cash flow 35,602M 479.58M Currency in INR Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
140,809M
142,028M
153,851M
174,600M
189,722M
Gross Profit
73,531M
71,189M
78,008M
88,078M
96,342M
Operating income
12,878M
11,182M
19,584M
28,637M
32,028M
Income before tax
14,304M
13,997M
22,005M
17,471M
25,933M
Net income
12,039M
9,806M
18,795M
19,498M
17,238M
EBITDA
24,155M
22,892M
31,774M
41,109M
44,824M
Diluted EPS
72.09
59.01
113.09
117.39
103.64
Dividends Per Share
20
20
20
25
25
Total Assets
219,821M
225,604M
225,427M
232,241M
265,491M
Total liabilities
95,777M
99,144M
85,230M
77,253M
92,429M
Total equity
124,044M
126,460M
140,197M
154,988M
173,062M
Operating cash flow
21,216M
17,110M
27,878M
29,249M
35,602M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
2,099.83M
2,203.14M
2,199.67M
2,462.41M
2,555.69M
Gross Profit
1,096.54M
1,104.28M
1,115.31M
1,242.17M
1,297.79M
Operating income
192.04M
173.45M
280.00M
403.87M
431.44M
Income before tax
213.31M
217.12M
314.61M
246.39M
349.33M
Net income
179.53M
152.11M
268.71M
274.98M
232.20M
EBITDA
360.21M
355.10M
454.28M
579.76M
603.81M
Diluted EPS
1.07
0.91
1.61
1.65
1.39
Dividends Per Share
0.29
0.31
0.28
0.35
0.33
Total Assets
3,385.24M
3,459.03M
3,254.08M
3,069.88M
3,631.20M
Total liabilities
1,474.96M
1,520.10M
1,230.31M
1,021.17M
1,264.18M
Total equity
1,910.27M
1,938.92M
2,023.77M
2,048.71M
2,367.02M
Operating cash flow
316.38M
265.41M
398.58M
412.50M
479.58M
Valuation Measures
Mar 2021
PER 43.44 ROA 6.92% ROE 10.50% Operating margin 16.88% Profit margin 9.08%
Key executives
Chief Executive Officer:
Erez Israeli
Chief Financial Officer:
Parag Agarwal
Chief Digital & Information Officer:
Mukesh Rathi
Secretary & Compliance Officer:
Sandeep Poddar
CEO-India & Emerging Markets Branded Markets:
M. V. Ramana Shareholders
Dr. Reddy's Holdings Ltd. (24.8%)
First Sentier Investors (Australia) IM Ltd. (3.5%)
Life Insurance Corp of India (2.3%)
SBI Funds Management Pvt Ltd. (2.1%)
Aditya Birla Sun Life Amc Ltd. (Investment Management) (1.9%)
BlackRock Fund Advisors (1.8%)
GIC Pte Ltd. (Investment Management) (1.7%)
The Vanguard Group, Inc. (1.5%)
ICICI Prudential Life Insurance Co. Ltd. (Invt Port) (1.3%)
Mirae Asset Financial Services (India) Pvt Ltd. (1.2%)
Contact Details Website: http://www.drreddys.com Address:
Door No. 8-2-337,
Road No. 3,
Hyderabad,
500034,
India
Phone:
+91.40.49002900
Related Companies
Dr. Reddy's Farmaceutica do Brasil Ltda.
Dr. Reddy's Employees ESOS Trust
Dr. Reddy's Research Foundation
BMS Laboratories Ltd.
Wockhardt Ltd. /Domestic Formulations Bus/
Imperial Credit Pvt Ltd.
Ducere Pharma LLC/Otc Bus/
UCB SA /Established Product Bus/
Dr. Reddy's Laboratories SA
Zenovus Biotech Pvt Ltd.
Regkinetics Services Ltd.
Dr. Reddy's Bio-Sciences Ltd.
Idea2Enterprises (India) Pvt Ltd.
Industrias Quimicas Falcon de Mexico SA de CV
Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
Aurigene Discovery Technologies Ltd.
Perlecan Pharma Pvt Ltd.
Macred India Pvt Ltd.
BASF SE /Pharmaceutical Contract Manufacturing Unit/
Dowpharma /Small Molecules Business/
Laboratorios Litaphar SA
F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
Trigenesis Therapeutics, Inc.
Competitors
Amneal Pharmaceuticals, Inc. Class A
Perrigo Co. Plc
KRKA dd
Teva Pharmaceutical Industries Limited
Novartis AG
Pfizer Limited
Pfizer Inc.
Sanofi
Hikma Pharmaceuticals Plc
Glenmark Pharmaceuticals Limited
Bayer AG
Lupin Limited
Aurobindo Pharma Ltd
Cipla Ltd
Alkem Laboratories Ltd.
Fresenius SE & Co. KGaA
Cadila Healthcare Limited
Nichi-Iko Pharmaceutical Co., Ltd.
Sanofi India Limited
Sun Pharmaceutical Industries Limited
Abbott India Limited
Viatris, Inc.
STADA Arzneimittel AG
GlaxoSmithKline Pharmaceuticals Limited
Piramal Enterprises Ltd.
Syngene International Ltd.
Endo International Plc
Hindustan Unilever Limited
WuXi AppTec Co., Ltd. Class H
Lonza Group AG
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 14 Oct, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
